Enzamide 40mg tablet | Enzalutamide | MHP

                                          ENZAMIDE

DESCRIPTION

           Enzalutamide is an active ingredient of Enzamide 40mg tablets available in the strength of 40mg. Enzamide 40mg tablets are used to treat the metastatic prostate cancer, in men. Enzamide 40mg is exhibits its action by stopping the advancement of tumor cells by blockade of androgen hormones especially testosterone.

          Enzamide 40mg containing Enzalutamide is also categorized as an anti-androgen chemo medicine. Enzamide 40mg tablets is not self medication; it is used under the knowledge of medical oncologist.

Enzamide 40mg Tablets

ENZAMIDE 40MG TABLETS USES

        Enzamide 40mg tablets are prescribing for; Metastatic or long lasting castration resistant prostate cancer.

ENZAMIDE 40MG TABLETS MECHANISM

       Enzamide 40mg containing anti-androgen agent like Enzalutamide, it expels an anti-tumor activity in different steps. Enzamide 40mg tablets are interfere in androgen receptor signaling pathway, which prohibiting androgen binding to androgen receptors leads to androgen receptor nuclear translocation inhibition and interact with DNA. The major metabolite of Enzamide 40mg is N-desmethyl Enzalutamide which is similar to Enzalutamide activity. The anti-tumor activity of Enzamide 40mg tablets is exposed by depleting the multiplication and persuades cell lysis in prostate cancer cells.

PRODUCTS DETAILS

Brand : Enzamide
Ingredients : Enzalutamide
Strength : 40mg
Manufactured : Intas
Package : 28 Tablets

ADME PROPERTIES

          After an oral administration of Enzamide 40mg tablets (160mg of dose), undergoes ADME process and exhibits activity. The peak plasma concentration time of Enzamide occurs at 1 hour with the range of 0.5 to 3 hours). The steady state of Enzamide 40mg occurs in day 28. The volume of distribution occur after single dose of Enzamide is 110L Enzamide has highly bounds to the human plasma protein with the range of 97 to 98%.

        The major metabolite of Enzalutamide is N-desmethyl Enzalutamide has 95% bound to human plasma protein. The most important isoenzymes responsible for the metabolism of Enzalutamide are CYP2C8 & CYP3A4. CYP2C8 is involved in the formation of an active metabolite N-desmethyl Enzalutamide. Enzamide 40mg tablets is majorly excreted through liver metabolism, 71% of metabolite present in urine and 14% in feces. The terminal half life period of Enzamide 40mg tablet is occurs after a single dose at 5.8days and N-desmethyl Enzalutamide is taken 7.8 to 8.6 days.

DOSAGE MANAGEMENT

       The usual recommended dosage of Enzamide is 160mg, but available strength of Enzamide 40mg Four tablets of Enzamide 40mg should be taken at a time as a single dose. Enzamide 40mg tablet should be administered with or without food.

      Dosing alteration: In ≥ grade 3 toxicity or extreme side effects: Postpone the dose of Enzamide for 1 week or as far as symptoms progress to ≤ grade 2, continue at the same or reduced to 120mg or 80mg. Concurrent use with strong CYP2C8 inhibitors:

      In case of combination with strong CYP2C8 inhibitors, diminish the dose of Enzamide to 80mg as a single dose. Concurrent use with strong CYP3A4 inducers: In case of combination with strong CYP3A4 inducers, increasing the dose of Enzamide 160mg to 240mg as a single dose.
ENZAMIDE 40MG TABLETS SAFETY PRECAUTIONS

The major adverse effect during the therapy of Enzamide tablets are;

SEIZURE

    Seizure may produce during the treatment with Enzamide 40mg tablets, if seizure occurs the treatment should be discontinued until seizure resolved. To avoid this condition, patient should be counsel about the problems occurred during the therapy before starting the treatment. Seizure may leads to loss of consciousness. 

POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME PRES

       Patient who are all taking Enzamide 40mg tablets acquired PRES, is a neurological problem produce symptoms like headache, lethargy, confusion, loss of vision, other neurological problems related with hypertension. PRES diagnosed by MRI. If patient acquired with PRES, discontinue the Enzamide therapy

ENZAMIDE 40MG TABLETS CAUSING SIDE EFFECTS

Asthenia
Peripheral edema
Back pain, arthralgia
Musculoskeletal pain
Muscular weakness
Musculoskeletal stiffness
Diarrhea
Hot flush
Hypertension
Headache
Dizziness
Spinal cord compression
Caude equine syndrome
Paresthesia
Mental disorders
Hypoesthesia
Respiratory tract infections
Insomnia
Anxiety
Hematuria
Pollakiuria
Non pathologic fractures
Pruritus
Dry skin
Epistaxis

PREGNANCY & LACTATION:

      The pregnancy category of Enzamide 40mg tablet is X Enzamide tablets are contraindicated to pregnancy conditions; it may cause fetal harm even to death. Enzamide 40mg tablets are contraindicated in lactation period, breast feeding should not be recommended.

STORAGE :

      The storage condition of Enzamide 40mg tablets container at 20°C to 25°C (68°F to 77°F). Container should be kept at dry and cool place.

MISSED DOSE:

     Enzamide 40mg is a chemo tablets, if patient fail to take the dose of Enzamide 40mg tablets must be consult with medical oncologist and take the dose within a time. In any other way the missed dose should be avoid and follow the regular dosing schedule.

OVER DOSAGE

       In case of over dosage of Enzamide 40mg tablets, patients must provided with some supportive measures and discontinue the therapy. The half life of Enzamide 40mg is occurs for 5.8 days. Seizure is the major adverse effect occurred due to over dosage of Enzamide 40mg . Seizure is not described at ≤240mg daily; since three seizures occurs at 360mg, 480mg and 600mg daily.

CONTACT DETAILS

Email :    millionhealthpharmaceuticals@gmail.com
Phone Number :   +91-9940472902
Website :     https://millionpharma.com/enzamide.php